Good And Bad News For Massachusetts Life Sci, Health Cos.

Law360, New York (October 10, 2017, 1:54 PM EDT) -- The number of securities class actions filed nationally against publicly traded pharmaceutical, biotechnology, medical device and health care product and services companies has skyrocketed in the last 18 months. These cases are typically filed by shareholders seeking to recover investment losses after a company’s stock price drops following the disclosure of a setback or problem experienced by the company with respect to its drugs or products, such as concerns, negative comments or regulatory action from the U.S. Food and Drug Administration, drug trial delays, suspensions or...
To view the full article, register now.